<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">problendo</journal-id><journal-title-group><journal-title xml:lang="ru">Проблемы Эндокринологии</journal-title><trans-title-group xml:lang="en"><trans-title>Problems of Endocrinology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0375-9660</issn><issn pub-type="epub">2308-1430</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/probl201662556-57</article-id><article-id custom-type="elpub" pub-id-type="custom">problendo-8120</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Краткое сообщение</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Short Messages</subject></subj-group></article-categories><title-group><article-title>Прогностические факторы интратиреоидальной папиллярной карциномы - мультивариантный анализ</article-title><trans-title-group xml:lang="en"><trans-title>Prognostic factors for intrathyroidal papillary carcinomas – a multivariate analysis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Santrac</surname><given-names>Nada Miroslav</given-names></name><name name-style="western" xml:lang="en"><surname>Santrac</surname><given-names>Nada Miroslav</given-names></name></name-alternatives><bio xml:lang="ru"><p>General surgery resident, Endocrine Surgery Department; Secretary of the Cancerology section of the Serbian Medical Society; Ambassador for SSSO in ESSO/EYSAC</p></bio><email xlink:type="simple">santrac.nada@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Markovic</surname><given-names>Ivan Zoran</given-names></name><name name-style="western" xml:lang="en"><surname>Markovic</surname><given-names>Ivan Zoran</given-names></name></name-alternatives><bio xml:lang="ru"><p>General Surgeon, Associate Professor of Surgery, Director of the Surgical Oncology Clinic</p></bio><bio xml:lang="en"><p>General Surgeon, Associate Professor of Surgery, Director of the Surgical Oncology Clinic</p></bio><email xlink:type="simple">ivanmarkovic66@yahoo.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Goran</surname><given-names>Merima Ramiz</given-names></name><name name-style="western" xml:lang="en"><surname>Goran</surname><given-names>Merima Ramiz</given-names></name></name-alternatives><bio xml:lang="ru"><p>General surgery resident</p></bio><bio xml:lang="en"><p>General surgery resident</p></bio><email xlink:type="simple">merimaoruci@hotmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Buta</surname><given-names>Marko Nikola</given-names></name><name name-style="western" xml:lang="en"><surname>Buta</surname><given-names>Marko Nikola</given-names></name></name-alternatives><bio xml:lang="ru"><p>General surgeon, Assistant Professor of Surgery, Chief of Endocrine Surgery Department</p></bio><bio xml:lang="en"><p>General surgeon, Assistant Professor of Surgery, Chief of Endocrine Surgery Department</p></bio><email xlink:type="simple">markobuta@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Djurisic</surname><given-names>Igor Dusan</given-names></name><name name-style="western" xml:lang="en"><surname>Djurisic</surname><given-names>Igor Dusan</given-names></name></name-alternatives><bio xml:lang="ru"><p>General surgeon, Chief of OR at the Surgical Oncology Clinic</p></bio><bio xml:lang="en"><p>General surgeon, Chief of OR at the Surgical Oncology Clinic</p></bio><email xlink:type="simple">drigordjurisic@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Dzodic</surname><given-names>Radan Radoslav</given-names></name><name name-style="western" xml:lang="en"><surname>Dzodic</surname><given-names>Radan Radoslav</given-names></name></name-alternatives><bio xml:lang="ru"><p>General surgeon – oncologist, Professor of Surgery, General Manager of the Institute for Oncology and Radiology of Serbia</p></bio><bio xml:lang="en"><p>General surgeon – oncologist, Professor of Surgery, General Manager of the Institute for Oncology and Radiology of Serbia</p></bio><email xlink:type="simple">radan.dzodic@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Institute for Oncology and Radiology of Serbia</institution><country>Сербия</country></aff><aff xml:lang="en"><institution>Institute for Oncology and Radiology of Serbia</institution><country>Serbia</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Institute for Oncology and Radiology of Serbia; University of Belgrade</institution><country>Сербия</country></aff><aff xml:lang="en"><institution>Institute for Oncology and Radiology of Serbia; University of Belgrade</institution><country>Serbia</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>22</day><month>09</month><year>2016</year></pub-date><volume>62</volume><issue>5</issue><issue-title>ТЕЗИСЫ ДОКЛАДОВ 4-й конференции Европейской ассоциации молодых эндокринологов</issue-title><fpage>56</fpage><lpage>57</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Santrac N.M., Markovic I.Z., Goran M.R., Buta M.N., Djurisic I.D., Dzodic R.R., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Santrac N.M., Markovic I.Z., Goran M.R., Buta M.N., Djurisic I.D., Dzodic R.R.</copyright-holder><copyright-holder xml:lang="en">Santrac N.M., Markovic I.Z., Goran M.R., Buta M.N., Djurisic I.D., Dzodic R.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.probl-endojournals.ru/jour/article/view/8120">https://www.probl-endojournals.ru/jour/article/view/8120</self-uri><abstract><p>Целью данного исследования явилось изучение прогностической факторов интратиреоидального папиллярного рака щитовидной железы (ПРЩЖ), связанных с пациентом, опухолью, а также лечением путем многофакторного анализа.</p><sec><title>Материал и методы</title><p>Материал и методы. В исследование было включено 153 пациента с интратиреоидальным ПРЩЖ (pT1 / pT2 / pt3), оперированных в нашем институте в течение 20 лет. Больные с местно-инвазивной опухолью (pT4) и начальными отдаленными метастазами (М1) в исследование включены не были. Область интересов данного исследования: пол (мужской, женский), возраст (&lt;= 45;&gt; 45 лет), размер опухоли (pTNM классификации ВОЗ 1984), мультифокальность (нет, да), гистологический тип ПРЩЖ (чистый; микрокарциномы; фолликулярная; слабо дифференцированы), наличие метастазов а лимфатические узлы (pN1a; ипсилатеральная-pN1b; контралатеральной-pN1b, общая), хирургии степени (тиреоидэктомии; тиреоидэктомии с лимфаденэктомией). С целью определения факторов, имеющих значение для выживаемости без признаков заболевания (DFS) и канцер-специфической общей выживаемости (cs-OS) был выполнен одномерный и многомерный анализ всех параметров.</p></sec><sec><title>Результаты</title><p>Результаты. В ходе исследования у 10% больных были выявлены локально-отграниченные или отдаленные рецидивы; 5,2% умерли из-за ПРЩЖ. Одномерный анализ выявил следующие неблагоприятные прогностические факторы для cs-OS: пожилой возраст, мужской пол, опухоли более 4см в диаметре, мультифокальность и малодиференцированный ПРЩЖ. Выживаемость без признаков заболевания (DFS) была значительно меньшей у мужчин, а также у пациентов с мультифокальной опухолью в сравнении одиночной ПРЩЖ. Мультифокальность опухоли является неблагоприятным прогностическим признаком как для DFS, так и для cs-OS. По результатам многофакторного анализа Кокса выявлены независимые прогностические факторы для интратиреоидального ПРЩЖ: мультифокальность и пол - для DFS, и мультифокальность и возраст на момент постановки диагноза для cs-OS.</p></sec><sec><title>Выводы</title><p>Выводы. прогностические факторы позволяют стратифицировать больных с PTCs по группам риска, обеспечить своевременное и адекватное лечение, а также обеспечить возможность улучшения качества жизни.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim: to examine prognostic significance of patient-related, tumor-related and treatment-related factors for intrathyroidal papillary thyroid carcinomas (PTC), via multivariate analysis.</p></sec><sec><title>Material and methods</title><p>Material and methods. This study included 153 patients with intrathyroidal PTCs (pT1/pT2/pT3) surgically treated in our Institution during two-decade period. Patients with locally invasive tumors (pT4) and initial distant metastases (M1) were excluded. Parameters of interest were: gender (male; female), age (&lt;=45; &gt;45 years), tumor size (pTNM classification WHO 1984), multifocality (no; yes), histological type of PTC (pure; microcarcinoma; follicular; poorly differentiated), presence of lymphonodal metastases (pN1a; ipsilateral-pN1b; contralateral-pN1b; total), surgery extent (total thyroidectomy; total thyroidectomy with lymphonodal dissections). Univariate and multivariate analysis of all parameters was performed in order to distinguish factors of significance for disease-free survival (DFS) and cancer-specific overall survival (cs-OS).</p></sec><sec><title>Results</title><p>Results. In the follow-up, 10% of patients had locoregional or distant relapse, while 5.2% died due to PTC. Univariate analysis distinguished older age, male gender, tumors over 4cm in diameter, multifocality and poorly differentiated PTC-types as unfavorable prognostic factors for cs-OS. DFS was significantly shorter in males vs. females, as well as in patients with multifocal vs. solitary PTC. Tumor multifocality was unfavorable prognostic factor for both DFS and cs-OS. Independent prognostic factors for intrathyroidal PTCs, based on Cox multivariate analysis, were multifocality and gender for DFS, and multifocality and age at diagnosis for cs-OS.</p></sec><sec><title>Conclusions</title><p>Conclusions. Prognostic factors define risk groups within population of differentiated PTCs providing timely, adequate treatment and opportunity for longer quality life of patients with PTCs.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>папиллярный рак щитовидной железы</kwd><kwd>интратиреоидальный</kwd><kwd>прогностические факторы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>papillary thyroid carcinoma</kwd><kwd>intrathyroidal</kwd><kwd>prognostic factors</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
